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We retrospectively reviewed 67 patients with pure seminoma who were treated in our hospital between
1991 and 2009. Fifteen (22.4%) patients had metastatic or recurrent disease and underwent chemotherapy.
Induction chemotherapy provided freedom from disease with no recurrence in 9 patients. On the other
hand, 6 patients had chemotherapy-resistant seminoma (refractory group). We herein report the clinical
features of the refractory group. Although we could not determine the risk factors for refractory disease,
clinical stage III disease was resistant to induction chemotherapy. The refractory group consisted of 2
patients with recurrent disease after prophylactic radiation therapy for stage I disease, 1 with stage IIB and 3
with stage IIIC disease. In the refractory group, 3 patients obtained freedom from disease after additional
chemotherapy with salvage surgery. However, 3 patients died from cancer in spite of multiple salvage
treatments. Salvage radiation therapy was performed for inoperable metastatic disease in 3 patients and
might have contributed to disease control in 2 patients. Some patients with pure seminoma can develop
refractory disease, although the prediction is difficult. Multimodality therapy including salvage radiation
possibly provides survival benefit.
(Hinyokika Kiyo 57 : 487-490, 2011)






とから2)，International Germ Cell Consensus Classifi-



























療法は VIP 療法 (etoposide，ifosphamide，cisplatin），
VeIP 療法 (vinblastine，ifosphamide，cisplatin) を 行
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Table 1. Clinical characteristics of study patients
寛解例 難治例 P 値
n 9 6
年齢（歳) 37（31-49) 42（34-53) 0.17
臨床病期分類
(I/II/III) 4/5/0 2/1/3 0.22
病理学的深達度
(T1/T2/T3/T4) 4/2/2/1 1/2/2/1 0.37
Ⅰ期予防照射
(あり/なし) 2/2 2/0 0.35
IGCCC
(good/intermediate) 9/0 3/3 0.02
初診時 hCG 上昇 6（66％) 3（50％) 0.60









症例 3例はすべて IIIC であり，intermediate prognosis
group であったが，これらはすべて難治例となってい
た．




難治例の転移巣，治療内容，転帰を Table 2 に示し
た．初発病期はⅠ期予防照射後の再発が 2例で，両者
とも後腹膜に 30 Gy 照射後， 6 カ月前後で再発（左
鎖骨上窩リンパ節と傍大動脈リンパ節）が見られた．















BEP 3 cycles [PR]→RPLND [VC (＋)]→VeIP 2 cycles [PD]→IrN 3 cycles
[SD]→TIN 3 cycles [PR]→RPLND＋腎摘除 [VC (−)]→癌な し生存（35
カ月)
51.9
3 44 IIB 後腹膜
BEP3 cycles [PR]→RPLND [VC (−)]→縦隔再発→VIP 2 cycles [CR]→縦
隔 LND [VC (−)]→右鎖骨下再発→IrN 3 cycles [PD]→TGP 3 cycles [SD]





BEP 4 cycles [CR]→左鎖骨上窩再発→VeIP 4 cycles [PD]→TIN 2 cycles
[PD]→IrN 1 cycles [PD]→癌死 32.9
5 53 IIIC 後腹膜 骨，腎筋膜
BEP 3 cycles [CR]→後腹膜再発→VIP 2 cycles [PD]→XRT 後腹膜，骨（計
70 Gy) [SD]→癌死 21.8
6 48 IIIC 後腹膜 肝
BEP 4 cycles [PR]→後腹膜再発→VeIP 2 cycles [PR]→RPLND [VC (−)]
→後腹膜再発→XRT (40 Gy)→肝再発→TIN 5 cycles [PR]→肝切除 [VC
(−)]→癌なし生存（13カ月)
27.2
LND : lymph node dissection, RPLND : retroperitoneal lymph node dissection, CR : complete response, PR : partial response, SD : stable
disease, PD : progressive disease, VC : viable cell, XRT : X-ray radiation treatment, BEP : bleomycin＋etoposide＋cisplatin, VIP : etoposide
＋ ifosphamide＋cisplatin, VeIP : vinblastine＋ ifosphamide＋cisplatin, IrN : irinotecan＋nedaplatin, TIN : paclitaxel＋ ifosphamide＋
nedaplatin, TGP : paclitaxel＋gemcitabine＋cisplatin.
IIIC 期は 3 例であり，導入時に骨，腎筋膜，肝に節
外転移巣を認めた．BEP 療法にて 3 例で一時 com-
plete response (CR) が得られたが，すべて 3カ月以内







リンパ節など 5 カ所に対して計 218 Gy 照射）を続
け，化学療法断念後40カ月の生存が得られた．Stage

























































のレジメンとして，BEP 療法に paclitaxel を追加した
T-BEP 療法が検討中であり，今後の結果が待たれ
る15)．




用したレジメンを用い，症例 2と 6の 2例で TIN 療
法後に surgical CR が得られ，現在長期生存中である．
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